Alkem Laboratories Ltd (NSE: ALKEM, BSE: 539523) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹60,380 Cr, it ranks #173 by market cap among the 6,137 Indian listed companies on FinBizNet, and #10 of 86 in Medicinal Chemicals and Botanical Products. At ₹4,947.00 (as of 25 Oct 2026), the share price is 16.6% below its 52-week high of ₹5,933.50 and 2.8% above its 52-week low of ₹4,811.00. The share price is down 11.1% over one year and down 12.2% over three months.
| Current Price | ₹4,947.00 |
|---|---|
| Market Cap | ₹60,380 Cr |
| NSE Symbol | ALKEM |
| BSE Code | 539523 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 25.9 |
| Return on Equity | 17.56% |
| Return on Assets | 8.43% |
| 52-Week Range | ₹4,811.00 – ₹5,933.50 |
| 1-Year Price Change | -11.1% |
| 3-Month Price Change | -12.2% |
| Beta (1Y) | 0.29 |
| Dividend Yield | 0.40% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.alkemlabs.com |
| Revenue | ₹3,740 Cr |
|---|---|
| Net Profit | ₹521 Cr |
| Net Margin | 13.9% |
| EPS (Basic) | ₹43.49 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.
1. Pharmaceuticals-This segment develops, manufactures, and sells pharmaceutical and nutraceutical products. 2. Investing-0 3. Corporate-This segment invests in real estate for rent. 4. Segment Adjustment-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Alkem Laboratories Ltd | ₹60,380 Cr | 25.9 | 17.56% | ₹3,740 Cr | -11.1% |
Listed by market capitalisation. Ratios are shown for context only.
Alkem Laboratories Ltd is trading at ₹4,947.00, with a market capitalisation of ₹60,380 Cr.
Alkem Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Alkem Laboratories Ltd has a P/E of 25.9 and a return on equity of 17.56%.
Alkem Laboratories Ltd is listed on the NSE under the symbol ALKEM and on the BSE under the scrip code 539523.
Alkem Laboratories Ltd's share price is down 11.1% over one year and down 12.2% over three months. Its 52-week range is ₹4,811.00 to ₹5,933.50.
In Q1 FY27, Alkem Laboratories Ltd reported revenue of ₹3,740 Cr and net profit of ₹521 Cr, with basic EPS of ₹43.49 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.